HC Wainwright Rates AnaptysBio (ANAB) buy, $95 Price Target
HC Wainwright has raised its rating on AnaptysBio, Inc. to buy with a price target of $95.00, a 66.96% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated AnaptysBio, Inc. ($ANAB) "buy" with a $95 price target on June 10, 2026.
Since the rating, $ANAB is up 9.0% after 1 week, up 27.4% after 1 month and down 10.5% to date (from the $52.10 close on Jun 10, 2026).
ANAB
AnaptysBio, Inc.
Key Points
- On June 10, 2026, HC Wainwright raised its rating on AnaptysBio, Inc. (ANAB) to buy, targeting $95.00, up from its previous close of $55.20.
- HC Wainwright's $95 price target implies 66.96% upside from AnaptysBio, Inc.'s ($ANAB) current $56.90 share price.
- AnaptysBio focuses on immunology therapeutics for autoimmune diseases, with products like Rosnilimab and ANB033 currently in different phases of clinical trials.
- Analysts have a consensus recommendation of strong buy for AnaptysBio, with an average price target of $89.63 from eight analysts.
Get $ANAB trade alerts by text
We text you when insiders, Congress or big funds trade $ANAB. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated AnaptysBio, Inc. alert may contain errors. Disclosures
HC Wainwright Upgrades AnaptysBio
HC Wainwright has raised its rating on AnaptysBio, Inc. (NasdaqGS: ANAB) to buy, setting a price target of $95.00. This upgrade came on June 10, 2026, following a previous close of $55.20. The firm's action suggests increased confidence in the company's potential.
Why the Upgrade Matters
The upgrade from HC Wainwright indicates a positive outlook for AnaptysBio. The new target price is significant compared to the stock's recent trading levels. The company's focus on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases positions it well within the competitive biotechnology sector.
Analysts Set New Price Targets
In addition to HC Wainwright, several other firms have provided recent ratings for AnaptysBio. JP Morgan maintains an Overweight rating with a target of $60.00 as of September 30, 2026. HC Wainwright also reiterated its buy rating with a consistent target of $95.00 on September 24, 2026. Leerink Partners is slightly more conservative, maintaining an Outperform rating with a target reduced to $81.00 on September 23, 2026. TD Cowen has also kept a Buy rating but lowered its target to $70.00 on August 25, 2026. This range of analyst opinions shows a generally positive sentiment towards AnaptysBio.
Current Stock Performance
As of the publication date, AnaptysBio's stock was trading at $56.90. This price sits comfortably above its 52-week low of $13.81, indicating strong growth potential. The company's recent developments and the raised target price reflect investor optimism, especially with its innovative drug pipeline.
$ANAB price target
AnaptysBio, Inc. daily closes and this analyst's $95 target. Not advice.
What AnaptysBio, Inc. Does
AnaptysBio, Inc. is a clinical-stage biotechnology company based in San Diego, California. It focuses on developing immunology therapeutics aimed at treating autoimmune and inflammatory diseases. Its leading products include Rosnilimab and ANB033, which are currently undergoing various clinical trials.
What’s Next for AnaptysBio
Looking ahead, AnaptysBio is scheduled to report its next earnings on September 21, 2026. The upcoming earnings report will provide further insights into the company's performance and may influence future analyst ratings. Remember, the recent rating changes from analysts reflect past evaluations and may not represent the current market position.
Related Filing Alerts
Source: HC Wainwright's rating change on $ANAB (Jun 10, 2026). Written by software, not financial advice. How we make alerts